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ased on WHO / National guideline criteria’s. Like ﬁrst line
RT combinations for initiating treatment and second line
RT combinations for treating ﬁrst line treatment failure
onditions. There are many combinations of ﬁrst line drugs
nd it is important to deﬁne are all these ﬁrst line regimens
qually effective in real clinical set ups.
Methods: We conducted a retrospective chart review
f the outcome of different ART regimens among 300
IV- infected patients whose CD4 count was less than
00 cells/mm3 on initiation of ART and has regular fol-
ow up at Gondar University Hospital in Gondar, Ethiopia
etween September 2008 and March 2009, who received
tandard ﬁrst line combination ART regimens. Group 1
N = 100) include those treated with AZT, 3TC, EFV/NVP
ombinations, Group 2 (N = 100) include those treated with
4T, 3TC, EFV/NVP combinations and Group 3 (N = 100)
nclude those treated with TDF, 3TC, EFV/NVP combina-
ions.
Results: There were no difference between Group 1,
and 3 with regard to: IRIS [Ten (10%), Thirteen (13%)
nd Eleven (11%), P = ns] respectively; new opportunistic
nfections [Four (4%), Seven (7%), and Three (3%), P = ns]
espectively; average CD4 increment by 30% [Eighty (80%),
eventy six (76%), and Eighty three (83%), P = ns] respec-
ively and death [Six (6%), Five (5%), and Four (4%), P = ns]
espectively. However, adverse drug side effect occurs more
requently in Group 1 and 2 than in Group 3 [Eighteen (18%)
nd Twenty (20%) versus Three (3%), P = 0.03] respectively,
hich more frequently resulted poor adherence in Group
and 2 than Group 3 [Seventeen (17%) and Sixteen (16%)
ersus Three (3%), P = 0.05] respectively.
Conclusion: This manuscript shows that in a retrospective
eview of HIV patients who are in different Antiretroviral
rug combination regimens attending follow ups at GUH,
he clinical and immunological responses for the different
RT regimens are similar and comparable however it depicts
ifferences in areas of drug side effects and adherence prob-
ems. Therefore different ﬁrst line ART drug combinations
election in resource poor countries can be guided by drugs
ide effect and adherence issues.
oi:10.1016/j.ijid.2010.02.2025
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omparison of efavirenz and nevirapine based HAART reg-
mens in 4187 patients with up to 6 years of follow up, a
rospective, open label observational study
. Cortes1,∗, C. Beltran2, M. Wolff 1
University of Chile School of Medicine, Chilean AIDS
ohort, Santiago, Chile
University of Santiago, Chilean AIDS Cohort, Santiago,
hile
Background: Non nucleoside reverse transcriptase
nhibitors (NNRTI) based regimens are widely recommended
s 1st line HAART and they are preferred in resource
onstrained settings due to high efﬁcacy and low cost. Few
tudies compare effectiveness of efavirenz (EFV) and nevi-
apine (NVP) in large, prospective cohorts with extended
ollow up (f/u). Objective: To determine the effectiveness,
ate of discontinuation or change, toxicity and mortality
o
d
i
bternational Congress on Infectious Diseases (ICID) Abstracts
f patients with EFV versus NVP based regimens as initial
AART in a nation wide cohort.
Methods: Prospective, open label, f/u of patients
nrolled in the Chilean AIDS Cohort (ChiAC) from October
001 to March 2008. All subjects receiving at least one dose
f EFV or NVP were included. Primary outcomes were sur-
ival, maintenance of initial HAART, reason for change of
NRTI, viral suppression and immune recovery.
Results: Of 5120 patients initiating ﬁrst HAART in ChiAC,
187 started a NNRTI based regimen (plus 2 NRTIs); 3107
74.2%) with EFV and 1080 (25.8%) with NVP. Median f/u
as 2.7 years. At baseline the NVP group had a signiﬁcantly
ess advanced stage (CDC classiﬁcation) and higher median
D4 count (151 vs 86 cell/mm3 in EFV, p < 0.001), but similar
iral load (VL) compared to the EFV group. Rate of change
r discontinuation was signiﬁcantly lower for EFV (12.8% vs
2.3%, p < 0.001), due to fewer adherence problems or toxi-
ity. Timing for change was similar in both arms (median 950
s 1008 days for EFV and NVP respectively). There were no
tatistical differences in viral suppression rate (<80 cps/mL)
t any time: 67.2, 74.9, 74.4, 65.1, 59.8% vs 63.6, 74.3,
2.7, 61.7, 59.4% at 6, 12, 24, 36 and 48 months for EFV
nd NVP respectively. At 12 months of f/u median CD4 cell
ount was similar for groups (242 for EFV and 250/mm3 for
VP). Mortality for the total period was 2.89 and 2.85 per
00pts-year for EFV and NVP respectively (p =NS).
Conclusion: Efavirenz based HAART regimens were asso-
iated with similar viral and immune outcomes as Nevirapine
ased regimens, despite more severe disease at baseline in
he EFV group. Discontinuation of NVP was more frequent,
ainly due to toxicity and lower adherence, but not to viral
ailure.
oi:10.1016/j.ijid.2010.02.2026
5.003
he economic impact of introducing HIV/AIDS guide-
ine into Colombian National Drug Formulary. Cost-
ffectiveness analysis
.V. Lemos Luengas ∗, B.C. Castan˜eda, E. Quevedo, C.
astillo, L.R. Lemos
Fundacion para el Desarrollo y Apoyo en Salud Internacional
FUDASAI), Bogota, Colombia
Background: Colombia has >165000 people infected
ith human immunodeﬁciency virus (HIV). In 2009, the
orld Health Organization (WHO) estimated only 40% had
ntiretroviral therapy coverage. Colombia’s AIDS treatments
uidelines became available in 2006 and are currently being
sed by physicians in their daily practice. However, these
uidelines have not yet been evaluated with respect to their
elative costs and effectiveness.
Methods: A Markov model was developed using TreeAge
Pro-2009 and clinical experts. Success probabilities were
erived from published randomized controlled trials. Drug
osts were obtained from the 2009 Drug Price Guideline from
ogotá and the ISS 2008 Manual. Hospitalization costs were
btained from theWest Kennedy Hospital, Bogotá 2008/2009
atabase, adjusted to 2008. One-way and two-way sensitiv-
ty analyses were performed to test the model’s robustness
y varying clinical success rates and costs of antiretrovirals.
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Probabilistic sensitivity analyses were also performed using
Monte Carlo simulations.
Results: Based on our Markov model, AZT-3TC-efavirenz
had the lowest cost of treatment (USD $12.09 per day)
and the highest rate of success (69%). It was the primary
cost-effective HAART for HIV/AIDS in Colombia. AZT-3TC-
efavirenz dominated all other HAART treatments. Results
were generally robust within ranges tested.
Conclusion: In Colombia, antiretroviral therapy will lead
to major survival beneﬁts and is cost-effective by World
Health Organization criteria. The availability of second-line
regimens will further increase survival, but their cost-
effectiveness depends on their relative cost compared with
ﬁrst-line regimens.
doi:10.1016/j.ijid.2010.02.2027
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Prevalence of metabolic abnormalities and metabolic syn-
drome in a cohort of hispanic patients on HAART
E. Bissio1,∗, G. Lopardo2
1 FUNCEI, Buenos Aires, Argentina
2 Corunna, Argentina
Background: Metabolic abnormalities are a well known
side-effect of HAART. However, some studies show similar
prevalences of metabolic syndrome in patients on HAART
and the general population. According to different studies,
prevalence of metabolic syndrome in the general popula-
tion ranges from 23.7% to 24.6% using the ATP III deﬁnition.
The aim of this study was to determine the prevalence
of metabolic abnormalities and metabolic syndrome in a
cohort of hispanic patients on HAART attending an ID Clinic
in Buenos Aires, Argentina.
Methods: Retrospective cross-sectional study. The
records from the patients were reviewed to determine
prevalence of the metabolic syndrome (as deﬁned by the
NCEP ATP III Update), and the prevalence of metabolic
abnormalities.
Results: The cohort was composed of 78 hispanic
patients on stable HAART for at least 6 months (mean age:
40.89± 8.55 years [range: 22—64]; 9% were women). Mean
CD4: 583± 282 cells/mm3; median VL: 50 (IQR: 50—50).
The general prevalence of the metabolic syndrome was
24.7% (95% CI 15.6-36.8). The prevalence among patients on
a protease inhibitor(PI)-based regimen (n = 15) was 26.7%,
versus 24.2% among those without PI (p =NS). In this last
group, those on efavirenz (n = 43) had a prevalence of 26.2%
compared to 14.3% those on nevirapine (p < 0.05). The age-
speciﬁc prevalence in the 30-39 years group was 22.2%, and
32.1% in the 40-49 years group. The prevalence of hyper-
trigliceridemia was 47.4%, but differed according to therapy
group (PI, EFV or NVP; mean values (mg/dL): 240± 322.76;
165± 109 and 150± 80.4; respectively), and increased with
age group (20-29: 33%, 30-39: 45.7%, 40-49: 50%). General
prevalence of low HDLwas 37.3% (women: 42%, men: 38.2%);
there was no difference between patients with or without
PI; but in this last group, prevalence among those on EFV was
42.5% vs 21.41% in those on nevirapine (p < 0.05). Hyperten-
sion prevalence was 39.5%.
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Conclusion: In this cohort, prevalence of the metabolic
yndrome was similar to the prevalence in the gen-
ral population. However, patients on protease inhibitors
nd efavirenz had a higher prevalence than those on
evirapine (and the general population). Drug-induced
ypertrigliceridemia seems to be one of the major drivers
eading to the emergence of the metabolic syndrome among
hese patients.
oi:10.1016/j.ijid.2010.02.2028
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edication errors in patients receiving antiretroviral
herapy at an urban hospital
. Zangeneh1,∗, G. Dickinson2
University of Miami, 33125, FL, USA
Miami VA Medical Center, Miami, ﬂ, USA
Background: Combination Antiretroviral therapy (ART)
as decreased morbidity and mortality for persons with
uman immunodeﬁciency virus (HIV) infection. These
omplex regimens involve three or more agents, and
here are many potential errors. The errors in prescrib-
ng ART may lead to adverse/toxic effects, treatment
ailure, and drug resistance. We evaluated medication
rrors occurring among patients receiving ART at the
iami VAMC to identify potential interventions to decrease
rrors.
Methods: This was a retrospective study utilizing a med-
cal chart review to evaluate medication prescribing errors
ccurring among patients who had received ART during Jan-
ary 1 through December 31, 2007 at the Miami VAMC.
sing the DHHS guidelines for HIV therapy as a source, we
creened for the following prescribing errors: inappropri-
te dosing, use of inappropriate regimens/combinations,
se of other medications and ART when contraindicated,
ailure to adjust for renal insufﬁciency, and insufﬁcient mon-
toring. In addition, we evaluated the frequency of errors
ccurring during admission in comparison to the out patient
linic.
Results: The medical charts of 833 patients of whom
14 (62%) were receiving ART were reviewed. A total of 24
igniﬁcant prescribing errors involving antiretrovirals were
etected. Themost common errors involved failure to adjust
or renal insufﬁciency (54%) followed by use of contraindi-
ated combinations with potential for drug interactions
46%). Overall, 17% of the errors occurred while the patient
as admitted to the hospital. Although 75% (3) of the errors
n the inpatient group were due to renal dosing as opposed to
5.5% (10) in the outpatient group; this was not statistically
igniﬁcant. Similarly, there was no statistical difference
egarding contraindicated combination medications among
oth groups.
Conclusion: In this Patient population, the most fre-
uent errors involved failure to adjust ART in the face
f renal insufﬁciency and the co-administration of con-
raindicated medications with ART. These errors can be
voided by automated alerts in the computerized medical
ecord used at this facility and emphasizing to physicians
he importance of adjusting dosage or changing the ART
o account for renal insufﬁciency. System-based interven-
